MIAMI, July 16,
2024 /PRNewswire/ - Avulux, the innovator behind the
only clinically proven lens that blocks the harmful light
wavelengths linked to migraine attacks, today announced that
Brant Southwell has joined the
company as Chief Commercial Officer. In this role, Mr. Southwell
will be responsible for leading Avulux's business-to-business
commercial strategy including sales, account management, strategic
partnerships, distribution, professional development, and marketing
integration.
"I'm absolutely thrilled to be part of the team bringing a
first-of-its-kind, clinically proven migraine and light sensitivity
lens to the market in a big way," said Mr. Southwell. "Avulux is
having a truly transformational impact on the standard of care in
optometry, bringing the medical model to life in eyecare practices
and empowering people who experience migraine to get back to the
activities they love. It's an exciting time to be in the optical
industry and I'm so pleased to be able to help eyecare
professionals broaden the impact they can have on the overall
health and wellness of their patients."
Mr. Southwell joins Avulux after approximately 15 years in sales
and marketing leadership roles in the eyecare industry, including a
decade at EssilorLuxottica where he launched and managed multiple
products and product lines, managed strategic partnerships, and led
key growth initiatives.
"We are delighted to welcome Brant
Southwell to Avulux," said Dr. Charles Posternack, Chief Executive Officer,
Avulux. "His expertise in developing and leading our comprehensive
commercial strategy, leveraging relationships with eyecare
providers, key opinion leaders, alliances and associations, lab
partners, trade associations, and clinical experts, will be
invaluable in helping to ensure that everyone experiencing migraine
and light sensitivity has access to Avulux technology through their
local eyecare professional."
About Avulux Migraine & Light
Sensitivity Lenses
Avulux is the world's only clinically proven lens that blocks
the harmful light wavelengths linked to migraine attacks. Up to 90
percent of people with migraine experience light sensitivity during
a migraine attack. The Avulux Migraine & Light Sensitivity Lens
is patented technology, blocking up to 97 percent of harmful blue,
amber and red light while letting in over 70 percent of soothing
green light.
The Avulux Migraine & Light Sensitivity Lens is available
through eyecare providers and optical retailers in the U.S.,
Canada, Australia, New
Zealand and the U.K. Learn more at ecp.avulux.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/brant-southwell-joins-avulux-as-chief-commercial-officer-302197345.html
SOURCE Avulux